Compass Therapeutics closed at $0.76 on Nov 4, up 1.29%, within 2.1% of its 52-week closing low. Volume of 1.9M shares was 0.64× its 20-day average (below normal).
Split-adjusted performance: -23.6% over one month, -59.2% over six months, -79.6% over one year.
Short interest was 41.8M shares at the Oct 15 settlement, up 3.7% from the prior report (33.9% of float, 5.6 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CMPXCompass Therapeutics | $0.7627 | +1.29% | −59.2% | — | — | — | $137.4M | |
| TARAProtara Therapeutics | $2.35 | −2.49% | −58.5% | — | — | — | $138.9M | Compare |
| CHRSCoherus Oncology | $0.8502 | +5.54% | −51.4% | +39.5% | −144.2% | — | $131.4M | Compare |
| HUMAHumacyte | $0.4500 | +2.16% | −54.2% | +34.9% | −9064.5% | — | $125.0M | Compare |
| AVXLAnavex Life Sciences | $1.26 | +5.00% | −62.3% | — | — | — | $116.8M | Compare |
| ARMPArmata Pharmaceuticals | $3.14 | +1.62% | −65.3% | +15.7% | 2953.8% | — | $116.8M | Compare |
| ENGNenGene Therapeutics | $1.72 | +6.17% | −80.6% | — | — | — | $115.3M | Compare |
| VYGRVoyager Therapeutics | $1.87 | +2.19% | −55.2% | −39.1% | −773.2% | — | $115.2M | Compare |
| STROSutro Biopharma | $9.94 | +4.52% | −73.6% | −84.6% | −391.6% | — | $164.8M | Compare |
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
